Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Table 8 Advances of MET-TKIs

Drug	Brand name	Manufacturer	Targets	Applications of diseases	Approved years or current phase of clinical trials
Capmatinib	Tabrecta	Novartis Oncology	MET	Metastatic METex14 + NSCLC	2020 [140]
Capmatinib	Tabrecta	Novartis Oncology	MET	Combined with gefitinib for MET-amplified EGFR-mutant NSCLC with required EGFR-TKI resistance	Ib/II [148]
Tepotinib	Tepmetko	Merck	MET	Metastatic METex14 + NSCLC	[137, 139] 2020 NDA accepted by FDA 2020 approved by MHLW
				Combined with gefitinib for MET-amplified EGFR-mutant NSCLC with required EGFR-TKI resistance	Ib/II [146]
				Combined with osimertinib for osimertinib relapsed MET-amplified EGFR-mutant NSCLC	II (NCT03940703)
Savolitinib	-	AstraZeneca and Chi-Med	MET	METex14 + PSC and other types of NSCLC Combined with osimertinib for osimertinib relapsed MET-amplified EGFR-mutant NSCLC	II [143] Ib [149] III(NCT03778229)

In the last column of “Approved years or current phases of clinical trials”: capmatinib was firstly approved by FDA; tepotinib was firstly approved by MHLW and also received an NDA from FDA; savolitinib was received a priority review by NMPA for metastatic METex14 + NSCLC. We also provided their current phases of clinical trials
PSC pulmonary sarcomatoid carcinoma, NSCLC non-small cell lung cancer, FDA Food and Drug Administration, NDA new drug application, MHLW Ministry of Health, Labor and Welfare, MET mesenchymal–epithelial transition factor, METex14 MET exon14 skipping alterations
Data source: www.fda.gov, www.drugs.com, and www.clinicaltrials.gov (cutoff date: 19 July 2020)

ISSN: 1756-8722